US FDA seeks more data from Dynavax's Heplisav hep B vaccine IND (PharmaBiz) PDF Print

Dynavax Technologies Corporation announced receipt of communication from the US Food and Drug Administration (FDA) regarding the clinical hold on the two Heplisav Investigational New Drug (IND) Applications, for healthy adults and patients with end-stage renal disease (ESRD).

read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.